Overview
Updated 14 Jul 2026
Claudio Anasetti, MD, is Emeritus Member, Department of Blood & Marrow Transplantation and Cellular Immunotherapy at H. Lee Moffitt Cancer Center and Research Institute (Emeritus). The public record shows 853 publications with 41,215 citations (h-index 107), centered on Lymphoma, Multiple Myeloma, Breast Cancer. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 2 companies, 6 NIH-funded awards (2004–2019).
- Most recent indexed publication: 2023 · Clinical cancer research
- Top research focus: Lymphoma
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
InvestigatorPhase 2CompletedNCT00803010 - Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Sponsor: Fred Hutchinson Cancer Center
InvestigatorPhase 2CompletedNCT00027924 - Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
Sponsor: Fred Hutchinson Cancer Center
InvestigatorPhase 2CompletedNCT00025545
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20258 payments
- Kite Pharma, Inc.Program year20248 payments
- Kite Pharma, Inc.Program year20233 payments
NIH funding
Updated 14 Jul 2026
6 NIH research awards on record, funded 2004–2019 per NIH RePORTER. The latest:
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Contact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mqa-internet.doh.state.fl.us ↗
- Fellowship in Hematology and Medical Oncology
University of Washington/Fred Hutchinson Cancer Research Center (1983-1989), with Dr. E. Donnall Thomas
1989provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biography.omicsonline.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biography.omicsonline.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- Founder/launched the Immune Cell Therapy Program at Moffitt Cancer Center (2015)
instrumental in clinical development leading to FDA approval of the first CD19-specific CAR T-cell therapy for relapsed/refractory …
2015provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biography.omicsonline.org ↗
Media & interviewspress, podcasts and appearances
- OncLive video interview: "Dr. Anasetti Discusses the Trade-offs of BMT and PBSC"
discusses phase III trial comparing bone marrow transplant vs. peripheral blood stem cell transplant from unrelated donors
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/claudio-anasetti-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Other
onclive.com/authors/claudio-anasetti-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Claudio-Anasetti-38604327
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.